Aesculap sees revival in Germany
This article was originally published in Clinica
Aesculap (Germany) has reported a 6.5% rise in turnover in the first six months of fiscal 1995. Sales totalled DM 272.8 million ($195 million) in the period, led by high growth in the service sector and a revival in the German market.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.